Verbio Vereinigte Bioenergie Ag Earnings Calls
| Release date | Sep 24, 2026 |
| EPS estimate | $0.293 |
| EPS actual | - |
| Revenue estimate | 612.559M |
| Revenue actual | - |
| Expected change | +/- 5.01% |
| Release date | May 13, 2026 |
| EPS estimate | $0.381 |
| EPS actual | $0.410 |
| EPS Surprise | 7.58% |
| Revenue estimate | 621.589M |
| Revenue actual | 516.566M |
| Revenue Surprise | -16.90% |
| Release date | Feb 12, 2026 |
| EPS estimate | $0.106 |
| EPS actual | $0.0587 |
| EPS Surprise | -44.44% |
| Revenue estimate | 590.779M |
| Revenue actual | 534.637M |
| Revenue Surprise | -9.50% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.0352 |
| EPS actual | -$0.0703 |
| EPS Surprise | -99.63% |
| Revenue estimate | 545.65M |
| Revenue actual | 513.277M |
| Revenue Surprise | -5.93% |
Last 4 Quarters for Verbio Vereinigte Bioenergie Ag
Below you can see how VBVBF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 12, 2025 |
| Price on release | $16.90 |
| EPS estimate | -$0.0352 |
| EPS actual | -$0.0703 |
| EPS surprise | -99.63% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $16.90 |
| Nov 07, 2025 | $16.90 |
| Nov 10, 2025 | $16.90 |
| Nov 11, 2025 | $16.90 |
| Nov 12, 2025 | $16.90 |
| Nov 13, 2025 | $16.90 |
| Nov 14, 2025 | $16.90 |
| Nov 17, 2025 | $16.90 |
| Nov 18, 2025 | $16.90 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Feb 12, 2026 |
| Price on release | $28.45 |
| EPS estimate | $0.106 |
| EPS actual | $0.0587 |
| EPS surprise | -44.44% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $16.90 |
| Feb 09, 2026 | $16.90 |
| Feb 10, 2026 | $16.90 |
| Feb 11, 2026 | $16.90 |
| Feb 12, 2026 | $28.45 |
| Feb 13, 2026 | $28.45 |
| Feb 17, 2026 | $28.45 |
| Feb 18, 2026 | $28.45 |
| Feb 19, 2026 | $28.45 |
| 4 days before | 68.34% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 68.34% |
| Release date | May 13, 2026 |
| Price on release | $43.00 |
| EPS estimate | $0.381 |
| EPS actual | $0.410 |
| EPS surprise | 7.58% |
| Date | Price |
|---|---|
| May 07, 2026 | $43.00 |
| May 08, 2026 | $43.00 |
| May 11, 2026 | $43.00 |
| May 12, 2026 | $43.00 |
| May 13, 2026 | $43.00 |
| May 14, 2026 | $47.24 |
| May 15, 2026 | $47.24 |
| May 18, 2026 | $47.24 |
| May 19, 2026 | $41.27 |
| 4 days before | 0% |
| 4 days after | -4.02% |
| On release day | 9.85% |
| Change in period | -4.02% |
| Release date | Sep 24, 2026 |
| Price on release | - |
| EPS estimate | $0.293 |
| EPS actual | - |
| Date | Price |
|---|---|
| Aug 04, 2026 | $44.05 |
| Aug 05, 2026 | $44.05 |
| Aug 06, 2026 | $44.05 |
| Aug 07, 2026 | $44.05 |
| Aug 10, 2026 | $44.05 |
Verbio Vereinigte Bioenergie Ag Earnings Call Transcript Summary of Q1 2026
Key points for investors: Verbio delivered strong operational and financial performance in Q1 2025/26 with record biodiesel production (~167,000 tonnes, ~94% utilization), ethanol production up 10% to 154,000 tonnes and biomethane +24% y/y driven by Nevada ramp-up. EBITDA turned positive to EUR 15.4m (from -EUR 6.6m), supported by higher co‑product revenues, favorable commodity forwards/FX and improved spreads, with the Biodiesel segment notably strong (EBITDA ~EUR 22.6m). Net financial debt rose due to temporary negative free cash flow from working capital timing effects and ~EUR 20m strategic investments (specialty chemicals unit in Bitterfeld, inventory/production investments in South Bend). Equity ratio remains healthy (~58%). Management keeps FY 2025/26 guidance unchanged (EBITDA expected in the high double‑digit million EUR range) but flags significant upside potential from higher GHG quota prices and RED III implementation while remaining cautiously conservative. Key operational focus areas: complete ramp-up and stable utilization in Nevada and South Bend (U.S.), finalize ethenolysis project in Bitterfeld, tight capex control and working capital optimization. RED III transposition (fraud prevention, removal of double counting, restrictions on denatured ethanol) is highlighted as an important medium-term positive for European ethanol pricing and quota dynamics. Management expects Q2 to be constructive and sees reduced downside risk and increased upside potential but will not adjust guidance until trends persist.
Sign In
Buy VBVBF